Bladder-PD-L1
| 22C3 PharmDx | 28-8 PharmDx | SP142 Assay | SP263 Assay | |
|---|---|---|---|---|
| Atezolizumab | - | - | 1L (≥5% IC) Companion | - |
| Durvalumab | - | - | - | - |
| Nivolumab | - | - | - | - |
| Pembrolizumab | 1L (≥10 CPS) Companion | - | - | - |
Therapies
1st line advanced or metastatic UC who are considered cisplatin ineligible – IC* ≥5% PD-L1 testing: companion
VENTANA PD-L1 (SP142) Assay
- OptiView and Amplification on a VENTANA BenchMark instrument
- Reference centres: AZ Delta, CHU Liège, Institut Jules Bordet, IPG, UZA, UZ Gent and UZ Leuven
- UC interpretation guide
- SP142 kit insert
* IC: proportion of tumour area occupied by PD-L1 expressing tumour-infiltrating immune cells (% IC) of any intensity
1st line advanced or metastatic UC who are considered cisplatin ineligible – CPS* ≥10 PD-L1 testing: companion
PD-L1 IHC 22C3 PharmDx
- EnVision FLEX visualization system on Autostainer Link 48/Omnis
- UC interpretation guide
- 22C3 PharmDx insert
* Combined Positive Score (CPS), which is the number of PD-L1 staining cells (tumour cells, lymphocytes, macrophages) divided by the total number of viable tumour cells, multiplied by 100. The specimen should be considered to have PD-L1 expression if CPS ≥ 10.